| Symbol | VANI |
|---|---|
| Name | VIVANI MEDICAL, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Address | 1350 S. LOOP ROAD, ALAMEDA, California, 94502, United States |
| Telephone | +1 415-506-8462 |
| Fax | — |
| — | |
| Website | https://www.vivani.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001266806 |
| Description | Vivani Medical Inc develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. Additional info from NASDAQ: |
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Read moreVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Read moreDwyer Donald 🟢 acquired 105.0K shares (2 derivative) of Vivani Medical, Inc. (VANI) at $1.31 Transaction Date: Jul 28, 2026 | Filing ID: 001286
Read morePorter Lisa Ellen 🟢 acquired 120.0K shares (2 derivative) of Vivani Medical, Inc. (VANI) at $1.31 Transaction Date: Jul 28, 2026 | Filing ID: 001285
Read moreBaldor Anthony 🟢 acquired 112.5K shares (2 derivative) of Vivani Medical, Inc. (VANI) at $1.31 Transaction Date: Jul 28, 2026 | Filing ID: 001284
Read moreLe Truc 🟢 acquired 240.0K shares (2 derivative) of Vivani Medical, Inc. (VANI) at $1.31 Transaction Date: Jul 28, 2026 | Filing ID: 001283
Read moreDirector Mendelsohn Adam 🟢 acquired 300.0K shares (2 derivative) of Vivani Medical, Inc. (VANI) at $1.31 Transaction Date: Jul 28, 2026 | Filing ID: 001282
Read moreDirector BRADBURY DANIEL 🟢 acquired 8.0K shares (1 derivative) of Vivani Medical, Inc. (VANI) at $1.30 Transaction Date: Jul 27, 2026 | Filing ID: 001243
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07430059 | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | Phase1 | Obesity & Overweight | Not_Yet_Recruiting | 2026-07-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT05670379 | Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Phase1 | Overweight and Obesity | Completed | 2024-12-20 | 2025-08-21 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE1 | Obesity & Overweight | NOT_YET_RECRUITING | NCT07430059 |
| Semaglutide Implant (NPM-139) | Other | Phase PHASE1 | Obesity & Overweight | NOT_YET_RECRUITING | NCT07430059 |
| Semaglutide, 1.0 mg/mL | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05670379 |
| Bydureon BCise (exenatide extended release) | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05670379 |
| Exenatide Implant | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05670379 |
| Semaglutide (Wegovy) weekly injection | Other | Phase PHASE1 | Obesity & Overweight | NOT_YET_RECRUITING | NCT07430059 |
| Semaglutide Implant (NPM-139) | Other | Phase PHASE1 | Obesity & Overweight | NOT_YET_RECRUITING | NCT07430059 |
| Semaglutide (Wegovy) weekly injection | DRUG | Phase PHASE1 | Obesity & Overweight | NOT_YET_RECRUITING | NCT07430059 |
| Semaglutide, 1.0 mg/mL | DRUG | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05670379 |
| Bydureon BCise (exenatide extended release) | DRUG | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT05670379 |